About
Luca Benatti is the Chief Executive Officer since June 2012. He has 27 year experience in Pharma and Biotech. He was Co-founder, CEO and Member of the Board of Newron Pharmaceuticals. Under his guidance, Newron developed a pipeline of innovative therapies, with most advanced compound safinamide now approaching worldwide regulatory filing for the treatment of Parkinson's disease. During his tenure, Newron raised significant capital from international venture capital firms, and was listed at the Swiss stock exchange. He also was instrumental in finalizing multimillion licensing deals with Merck Serono, Meiji Seika and Zambon, and in the acquisition of the UK biotech Company Hunter Fleming. Luca graduated and performed his post-doctoral training at Milano Genetics Institute. He is an independent Board member at Newron (Swiss Stock Exchange), Intercept Pharmaceuticals (Nasdaq), Chairman of the Scientific Advisory Board of Zambon, Vice President and member of the Board of Assobiotec a
Position in the VCSift Database
- • 8 investors hold the Chief Executive Officer and Board Member role in VCSift. Luca Benatti is one of them.
- • 603 investors are based in Milan, Lombardia, Italy.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Milan, Italy
Contact Information
Find more investors like Luca
Search Investors